Small molecule activation of pkm2 in cancer cells induces serine auxotrophy

Chemistry and Biology

Volumn 19, Issue 9, 2012, Pages 1187-1198

  Kung, Charles ^a   Hixon, Jeff ^a   Choe, Sung ^a   Marks, Kevin ^a   Gross, Stefan ^a   Murphy, Erin ^a   Delabarre, Byron ^a   Cianchetta, Giovanni ^a   Sethumadhavan, Shalini ^a   Wang, Xiling ^b   Yan, Shunqi ^f   Gao, Yi ^b   Fang, Cheng ^b   Wei, Wentao ^g   Jiang, Fan ^g   Wang, Shaohui ^b   Qian, Kevin ^g   Saunders, Jeff ^a   Driggers, Ed ^a   Woo, Hin Koon ^a   Kunii, Kaiko ^a   Murray, Stuart ^a   Yang, Hua ^a   Yen, Katharine ^a   Liu, Wei ^a   Cantley, Lewis C ^c,d   Vander Heiden, Matthew G ^d,e   Su, Shinsan M ^a   Jin, Shengfang ^a   Salituro, Francesco G ^a   Dang, Lenny ^a   more..

^a AGIOS PHARMACEUTICALS   (United States)

^b Shanghai ChemPartner Co Ltd   (China)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f SCHRÖDINGER INC   (United States)

^g Viva Biotech   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PHOSPHOENOLPYRUVATE; PYRUVATE KINASE; PYRUVATE KINASE M2; SERINE; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO ACID METABOLISM; ARTICLE; AUXOTROPHY; BINDING KINETICS; BIOSYNTHESIS; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; ENZYME ACTIVATION; ENZYME SUBSTRATE; GLUCOSE METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ALLOSTERIC SITE; CARRIER PROTEINS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SERINE; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; THYROID HORMONES; TUMOR CELLS, CULTURED;

EID: 84866697915     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2012.07.021     Document Type: Article

References (40)

1. D. Anastasiou, G. Poulogiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen, G. Bellinger, A.T. Sasaki, J.W. Locasale, and D.S. Auld Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses Science 334 2011 1278 1283
2. K. Ashizawa, M.C. Willingham, C.M. Liang, and S.Y. Cheng In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate J. Biol. Chem. 266 1991 16842 16846 (Pubitemid 21907876)
3. M.B. Boxer, J. Jiang, M.G. Vander Heiden, M. Shen, H. Veith, L.C. Cantley, and C.J. Thomas Identification of activators for the M2 isoform of human pyruvate kinase Version 3 Probe Reports from the NIH Molecular Libraries Program 2010 National Center for Biotechnology Information Bethesda, MD http://www.ncbi.nlm.nih.gov/books/NBK56225/
4. M.B. Boxer, J.K. Jiang, M.G. Vander Heiden, M. Shen, A.P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C.P. Austin, and H.W. Park Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase J. Med. Chem. 53 2010 1048 1055
5. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, and L.C. Cantley The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233 (Pubitemid 351380249)
6. H.R. Christofk, M.G. Vander Heiden, N. Wu, J.M. Asara, and L.C. Cantley Pyruvate kinase M2 is a phosphotyrosine-binding protein Nature 452 2008 181 186 (Pubitemid 351380242)
7. C.V. Clower, D. Chatterjee, Z. Wang, L.C. Cantley, M.G. Vander Heiden, and A.R. Krainer The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism Proc. Natl. Acad. Sci. USA 107 2010 1894 1899
8. T.J. de Koning, K. Snell, M. Duran, R. Berger, B.T. Poll-The, and R. Surtees L-serine in disease and development Biochem. J. 371 2003 653 661 (Pubitemid 36578864)
9. R.J. DeBerardinis, and T. Cheng Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer Oncogene 29 2010 313 324
10. J.D. Dombrauckas, B.D. Santarsiero, and A.D. Mesecar Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis Biochemistry 44 2005 9417 9429 (Pubitemid 40962040)
11. E. Eigenbrodt, M. Reinacher, U. Scheefers-Borchel, H. Scheefers, and R. Friis Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells Crit. Rev. Oncog. 3 1992 91 115
12. T. Fuhrer, D. Heer, B. Begemann, and N. Zamboni High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry Anal. Chem. 83 2011 7074 7080
13. X. Gao, H. Wang, J.J. Yang, X. Liu, and Z.R. Liu Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase Mol. Cell 45 2012 598 609
14. R.C. Gentleman, V.J. Carey, D.M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, and J. Gentry Bioconductor: open software development for computational biology and bioinformatics Genome Biol. 5 2004 R80
15. M.L. Graham Pegaspargase: a review of clinical studies Adv. Drug Deliv. Rev. 55 2003 1293 1302 (Pubitemid 37464563)
16. T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, and G.Z. Chen Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth Sci. Signal. 2 2009 ra73
17. K.H. Ibsen, and S.W. Marles Inhibition of chicken pyruvate kinases by amino acids Biochemistry 15 1976 1073 1079
18. R.A. Irizarry, B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, U. Scherf, and T.P. Speed Exploration, normalization, and summaries of high density oligonucleotide array probe level data Biostatistics 4 2003 249 264
19. J.K. Jiang, M.B. Boxer, M.G. Vander Heiden, M. Shen, A.P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C.P. Austin, and H.W. Park Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase Bioorg. Med. Chem. Lett. 20 2010 3387 3393
20. C. Jousse, C. Deval, A.C. Maurin, L. Parry, Y. Chérasse, C. Chaveroux, R. Lefloch, P. Lenormand, A. Bruhat, and P. Fafournoux TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway J. Biol. Chem. 282 2007 15851 15861 (Pubitemid 47093266)
21. J.W. Locasale, and L.C. Cantley Genetic selection for enhanced serine metabolism in cancer development Cell Cycle 10 2011 3812 3813
22. J.W. Locasale, A.R. Grassian, T. Melman, C.A. Lyssiotis, K.R. Mattaini, A.J. Bass, G. Heffron, C.M. Metallo, T. Muranen, and H. Sharfi Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis Nat. Genet. 43 2011 869 874
23. W. Luo, H. Hu, R. Chang, J. Zhong, M. Knabel, R. O'Meally, R.N. Cole, A. Pandey, and G.L. Semenza Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 145 2011 732 744
24. L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, and Y. Xu Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth Mol. Cell 42 2011 719 730
25. S. Mazurek, H. Grimm, C.B. Boschek, P. Vaupel, and E. Eigenbrodt Pyruvate kinase type M2: a crossroad in the tumor metabolome Br. J. Nutr. 87 Suppl 1 2002 S23 S29
26. C.M. Metallo, P.A. Gameiro, E.L. Bell, K.R. Mattaini, J. Yang, K. Hiller, C.M. Jewell, Z.R. Johnson, D.J. Irvine, and L. Guarente Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia Nature 481 2012 380 384
27. A.R. Mullen, W.W. Wheaton, E.S. Jin, P.H. Chen, L.B. Sullivan, T. Cheng, Y. Yang, W.M. Linehan, N.S. Chandel, and R.J. Deberardinis Reductive carboxylation supports growth in tumour cells with defective mitochondria Nature 481 2012 385 388
28. T. Noguchi, H. Inoue, and T. Tanaka The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing J. Biol. Chem. 261 1986 13807 13812 (Pubitemid 17196407)
29. S. Pollari, S.M. Käkönen, H. Edgren, M. Wolf, P. Kohonen, H. Sara, T. Guise, M. Nees, and O. Kallioniemi Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis Breast Cancer Res. Treat. 125 2011 421 430
30. R. Possemato, K.M. Marks, Y.D. Shaul, M.E. Pacold, D. Kim, K. Birsoy, S. Sethumadhavan, H.K. Woo, H.G. Jang, and A.K. Jha Functional genomics reveal that the serine synthesis pathway is essential in breast cancer Nature 476 2011 346 350
31. L. Schirch, and D. Peterson Purification and properties of mitochondrial serine hydroxymethyltransferase J. Biol. Chem. 255 1980 7801 7806
32. G.K. Smyth Linear models and empirical Bayes methods for assessing differential expression in microarray experiments Stat. Appl. Genet. Mol. Biol 3 2004 Article3
33. R. Stark, F. Pasquel, A. Turcu, R.L. Pongratz, M. Roden, G.W. Cline, G.I. Shulman, and R.G. Kibbey Phosphoenolpyruvate cycling via mitochondrial phosphoenolpyruvate carboxykinase links anaplerosis and mitochondrial GTP with insulin secretion J. Biol. Chem. 284 2009 26578 26590
34. L. Tian, S.A. Greenberg, S.W. Kong, J. Altschuler, I.S. Kohane, and P.J. Park Discovering statistically significant pathways in expression profiling studies Proc. Natl. Acad. Sci. USA 102 2005 13544 13549 (Pubitemid 41420885)
35. C.W. van Veelen, G.E. Staal, H. Verbiest, and A.M. Vlug Alanine inhibition of pyruvate kinase in gliomas and meningiomas. A diagnostic tool in surgery for gliomas? Lancet 2 1977 384 385 (Pubitemid 8164401)
36. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
37. M.G. Vander Heiden, S.Y. Lunt, T.L. Dayton, B.P. Fiske, W.J. Israelsen, K.R. Mattaini, N.I. Vokes, G. Stephanopoulos, L.C. Cantley, and C.M. Metallo Metabolic pathway alterations that support cell proliferation Cold Spring Harb. Symp. Quant Biol 76 2011 325 334
38. O. Warburg, F. Wind, and E. Negelein The metabolism of tumors in the body J. Gen. Physiol. 8 1927 519 530
39. W. Yang, Y. Xia, H. Ji, Y. Zheng, J. Liang, W. Huang, X. Gao, K. Aldape, and Z. Lu Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation Nature 480 2011 118 122
40. J. Ye, M. Kumanova, L.S. Hart, K. Sloane, H. Zhang, D.N. De Panis, E. Bobrovnikova-Marjon, J.A. Diehl, D. Ron, and C. Koumenis The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation EMBO J. 29 2010 2082 2096